(MedPage Today) — Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy in patients who had clinical complete response did not reliably predict pathological complete response (pCR) among breast cancer patients, findings…

Read the full article on medpagetoday.com